Cost-effectiveness of eplerenone in patients with systolic heart failure and mild symptoms

Source: Heart online first

Follow this link for fulltext

Date of publication: July 2014

Publication type: Research

In a nutshell: Results from the EMPHASIS-HF trial (‘Eplerenone in Mild Patients Hospitalization and Survival Study in Heart Failure’) were used to develop a simulation model estimating lifetime direct costs of prescribing eplerenone to patients with chronic systolic heart failure (HF). Eplerenone was regarded as cost-effective at a willingness-to-pay threshold of £20 000 per QALY (Quality-Adjusted Life Years).

Length of publication: 7 pages

Some important notes: Please contact your local NHS library if you cannot access the full text. Follow this link to find your local NHS library.

Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google photo

You are commenting using your Google account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )

Connecting to %s

%d bloggers like this: